Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2056-5968
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies ; volume:8 ; number:1 ; day:7 ; month:10 ; year:2022 ; pages:1-15 ; date:12.2022
Cell discovery ; 8, Heft 1 (7.10.2022), 1-15, 12.2022
- Urheber
-
Wang, Yingdan
Zhang, Xiang
Ma, Yunping
Wang, Yanqun
Zhan, Wuqiang
Zheng, Qinwen
Zhang, Meng
Ji, Ping
Liu, Mei
Liu, Qianying
Sun, Tingting
Zhu, Tongyu
Wen, Yumei
Sun, Lei
Zhao, Jincun
Wu, Fan
Chen, Zhenguo
Huang, Jinghe
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41421-022-00463-6
- URN
-
urn:nbn:de:101:1-2022122321114298050107
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wang, Yingdan
- Zhang, Xiang
- Ma, Yunping
- Wang, Yanqun
- Zhan, Wuqiang
- Zheng, Qinwen
- Zhang, Meng
- Ji, Ping
- Liu, Mei
- Liu, Qianying
- Sun, Tingting
- Zhu, Tongyu
- Wen, Yumei
- Sun, Lei
- Zhao, Jincun
- Wu, Fan
- Chen, Zhenguo
- Huang, Jinghe
- SpringerLink (Online service)
Ähnliche Objekte (12)
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Bispecific antibodies
Bispecific antibodies
In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Meteorological factors driving glacial till variation and the associated periglacial debris flows in Tianmo Valley, south-eastern Tibetan Plateau
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Bispecific antibodies
Bispecific antibodies
In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Meteorological factors driving glacial till variation and the associated periglacial debris flows in Tianmo Valley, south-eastern Tibetan Plateau
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees
BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
Bispecific antibodies
Bispecific antibodies
In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Meteorological factors driving glacial till variation and the associated periglacial debris flows in Tianmo Valley, south-eastern Tibetan Plateau
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease